

Supplementary Table 1. Demographic and Baseline Characteristics of Patients Enrolled in the VISIBLE 1 Study (SAF-C)^a

Variable	Induction phase		Maintenance phase (FAS)		
	Vedolizumab IV (n = 167)	Placebo (n = 56)	Vedolizumab SC (n = 106)	Vedolizumab IV (n = 54)	Total (n = 216)
Age (yr) ^b	42.7 ± 15.01	39.4 ± 11.70	38.1 ± 13.12	41.6 ± 14.11	39.3 ± 13.05
Male sex	88 (52.7)	34 (60.7)	65 (61.3)	31 (57.4)	130 (60.2)
Race					
American Indian or Alaskan Native	2 (1.2)	1 (1.8)	0	0	1 (0.5)
Asian	39 (23.4)	13 (23.2)	14 (13.2)	5 (9.3)	32 (14.8)
Black or African American	1 (0.6)	0	0	2 (3.7)	2 (0.9)
Native Hawaiian or other Pacific Islander	0	0	0	0	0
Caucasian	125 (74.9)	42 (75.0)	92 (86.8)	47 (87.0)	181 (83.8)
Multiracial ^c	0	0	0	0	0

Values are presented as mean ± standard deviation or number (%).

^aIncluded all randomized patients (n = 216) who received at least 1 dose of study drug.

^bAge at date of informed consent.

^cPatient checked more than 1 race option on the case report form.

SAF-C, safety analysis set-combined; FAS, full analysis set; IV, intravenous; SC, subcutaneous.

Supplementary Table 2. Fecal Calprotectin by Visit (FAS)

Variable	Maintenance phase (FAS)		
	Placebo	Vedolizumab SC	Vedolizumab IV
Baseline, No.	10	10	2
Median (min, max) (µg/g)	1,145.5 (60, 13,620)	4,306.5 (779, 15,445)	6,812.0 (2,240, 11,384)
Week 6, No.	10	10	2
Median (min, max) (µg/g)	1,353.5 (43, 43,503)	374.5 (33, 76,800)	1,686.5 (784, 2,589)
Week 30, No.	9	10	1
Median (min, max) (µg/g)	322.0 (18, 73,172)	184.5 (15, 76,800)	26
Week 52, No.	2	8	1
Median (min, max) (µg/g)	49.0 (48, 50)	143.5 (32, 319)	16

FAS, full analysis set; SC, subcutaneous; IV, intravenous; min, minimum; max, maximum.